Skip to main content
ProMIS Neurosciences Inc. logo

ProMIS Neurosciences Inc. — Investor Relations & Filings

Ticker · PMN ISIN · CA74346M1095 LEI · 5299007HZF79F9IAXI53 US Professional, scientific and technical activities
Open in API
Filings indexed 333 across all filing types
Latest filing 2024-02-05 Major Shareholding Noti…
Country CA Canada
Listing US PMN

About ProMIS Neurosciences Inc.

https://www.promisneurosciences.com/

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company focused on the discovery and development of selective antibody therapeutics for neurodegenerative and other misfolded protein diseases. The company leverages a proprietary technology platform to design and generate antibodies that selectively target toxic oligomers, which are key drivers of diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), Parkinson’s disease (PD), and multiple system atrophy (MSA). Its lead product candidate, PMN310, is in clinical development for Alzheimer's disease. The company's approach aims to provide effective treatments while potentially reducing side effects associated with less specific therapies.

Recent filings

Filing Released Lang Actions
SC 13G/A
Major Shareholding Notification
2024-02-05 English
8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated January 5, 2024, by ProMIS Neurosciences Inc. It announces the entry into a material definitive agreement for an At The Market Offering Agreement with BTIG, LLC, allowing the company to sell common shares up to $25 million. The document includes details about the offering, the agent's role, and related exhibits such as the agreement and legal opinion. There are no financial statements or quarterly/yearly financial results presented, nor is this a transcript, management report, or governance document. The primary content is an update on a financing activity (capital raising) through an at-the-market offering. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length (6070 characters) and content confirm it is a substantive filing, not just an announcement of a report. Confidence is high due to clear identification of the offering agreement and related financing details.
2024-01-05 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act of 1933, related to an 'At The Market' offering of common shares by ProMIS Neurosciences Inc. It includes detailed information about the offering, risk factors, use of proceeds, dilution, plan of distribution, and legal matters. The document is a formal registration and offering document used to raise capital through the sale of shares. This type of document is best classified as a Capital/Financing Update (CAP) because it provides updates on the company's fundraising activities and capital structure changes. It is not an annual or interim report, earnings release, or any other category. The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or a brief summary, so it is not an RPA or RNS. Therefore, the correct classification is CAP with high confidence.
2024-01-05 English
PRIMARY DOCUMENT
Director's Dealing
2024-01-05 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated December 30, 2023, reporting a leadership change: the departure of the CEO and appointment of a new interim CEO. The content focuses on management changes, including details about the new CEO's background, employment agreement, and severance arrangements for the departing CEO. There are no financial statements or financial performance data presented. The primary subject is the announcement of changes in the company's board of directors and senior management. According to the filing definitions, this fits the category of Board/Management Information (MANG). The document length (7762 characters) is sufficient to be a full report rather than a brief announcement. Therefore, the classification is MANG with high confidence.
2024-01-03 English
SC 13G/A
Major Shareholding Notification
2024-01-02 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.